Shionogi License Agreement was Maze Therapeutics’s largest revenue line in fiscal 2024, bringing in $150.00M of $167.50M (90%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2024 |
|---|---|
| Shionogi License Agreement | $150.00M |
| Trace License Agreement | $15.00M |
| Neurocrine License Agreement | $2.50M |
| Total | $167.50M |
Maze Therapeutics brought in $167.50M from its three revenue lines in fiscal 2024, the year ended December 31, 2024. Shionogi License Agreement was the largest at $150.00M (89.6%), ahead of Trace License Agreement at $15.00M (9.0%) and Neurocrine License Agreement at $2.50M (1.5%).
Maze Therapeutics (MAZE) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2024, Shionogi License Agreement was its largest revenue line, bringing in $150.00M (89.6% of the total), followed by Trace License Agreement at $15.00M (9.0%).
Shionogi License Agreement was Maze Therapeutics' largest revenue line in fiscal 2024, bringing in $150.00M, or 89.6% of the $167.50M total across its three revenue lines.
Every figure comes from Maze Therapeutics' annual financial filings, as reported. Each line keeps the name Maze Therapeutics gives it, and years follow its fiscal calendar.
Maze Therapeutics' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2024, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.